2023 North America Conference on Lung Cancer (NACLC) - Posters and Abstracts-PP01.10 (Poster) Real-World Outcomes of Patients with Advanced EGFR-Mutated NSCLC in Canada Using AI-Extracted Data

PP01.10 (Poster) Real-World Outcomes of Patients with Advanced EGFR-Mutated NSCLC in Canada Using AI-Extracted Data

Pdf Summary

A study presented at the North America Conference on Lung Cancer in December 2023 examined the real-world outcomes of patients with advanced epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) in Canada. The study used artificial intelligence to extract data from electronic health records of patients seen at the University Health Network between January 2017 and March 2022. The study included 613 patients with advanced NSCLC, with 22% having common EGFR mutations, 1% having exon 20 insertion mutations, 55% having EGFR wild-type tumors, and 21% not having testing conducted at the University Health Network. The study found that survival post-osimertinib, a targeted therapy for EGFR-mutated NSCLC, was poor in patients with common EGFR sensitizing tumoral mutations. However, patients with exon 20 insertion mutations experienced improved outcomes, possibly due to innovative treatments targeting these mutations. The study emphasized the need for more effective therapies, particularly for patients with common EGFR mutations. The study also highlighted the importance of early treatment initiation for these patients. The findings support the need for the approval of novel, effective therapies for patients with advanced EGFR-mutated NSCLC. The study was supported by Janssen Canada and the Princess Margaret Cancer Foundation. The authors of the study disclosed their affiliations and any conflicts of interest.

Asset Subtitle

Ruth Moulson

Keywords

North America Conference on Lung Cancer

study

patients

advanced NSCLC

EGFR mutations

exon 20 insertion mutations

survival

targeted therapy

innovative treatments

early treatment initiation